Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Other Non-Current Liabilities (2019 - 2025)

Historic Other Non-Current Liabilities for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $6.7 million.

  • Beam Therapeutics' Other Non-Current Liabilities rose 2714.18% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year increase of 2714.18%. This contributed to the annual value of $5.4 million for FY2024, which is 9845.76% up from last year.
  • As of Q3 2025, Beam Therapeutics' Other Non-Current Liabilities stood at $6.7 million, which was up 2714.18% from $6.5 million recorded in Q2 2025.
  • Beam Therapeutics' 5-year Other Non-Current Liabilities high stood at $37.6 million for Q2 2021, and its period low was $1.1 million during Q2 2024.
  • Its 5-year average for Other Non-Current Liabilities is $16.0 million, with a median of $10.6 million in 2023.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first soared by 915098.52% in 2021, then plummeted by 8982.81% in 2024.
  • Over the past 5 years, Beam Therapeutics' Other Non-Current Liabilities (Quarter) stood at $31.4 million in 2021, then crashed by 60.27% to $12.5 million in 2022, then tumbled by 78.15% to $2.7 million in 2023, then surged by 98.46% to $5.4 million in 2024, then rose by 24.13% to $6.7 million in 2025.
  • Its last three reported values are $6.7 million in Q3 2025, $6.5 million for Q2 2025, and $6.3 million during Q1 2025.